Trial Profile
An Open-label, Randomized Phase I Study Investigating Safety, Tolerability, Pharmacokinetics, and Efficacy of Pembrolizumab (MK-3475) in Chinese Subjects With Non-Small-Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Oct 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Pharmacokinetics
- Acronyms KEYNOTE-032
- Sponsors Merck Sharp & Dohme Corp.
- 25 May 2021 Planned End Date changed from 25 Apr 2021 to 26 Dec 2021.
- 01 Aug 2020 Status changed to completed , according to Results presented at the 19th World Conference on Lung Cancer
- 31 May 2019 Planned End Date changed from 30 Apr 2019 to 25 Apr 2021.